X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs AUROBINDO PHARMA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB AUROBINDO PHARMA DR. REDDYS LAB/
AUROBINDO PHARMA
 
P/E (TTM) x 33.8 18.5 182.8% View Chart
P/BV x 3.3 6.0 55.3% View Chart
Dividend Yield % 0.8 0.3 235.8%  

Financials

 DR. REDDYS LAB   AUROBINDO PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-17
AUROBINDO PHARMA
Mar-16
DR. REDDYS LAB/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs3,3971,541 220.5%   
Low Rs2,560582 439.9%   
Sales per share (Unadj.) Rs856.5237.5 360.7%  
Earnings per share (Unadj.) Rs78.033.9 230.2%  
Cash flow per share (Unadj.) Rs139.940.6 344.8%  
Dividends per share (Unadj.) Rs20.002.50 800.0%  
Dividend yield (eoy) %0.70.2 285.1%  
Book value per share (Unadj.) Rs739.8120.6 613.5%  
Shares outstanding (eoy) m165.74585.17 28.3%   
Bonus/Rights/Conversions BBPREF-  
Price / Sales ratio x3.54.5 77.8%   
Avg P/E ratio x38.231.3 121.9%  
P/CF ratio (eoy) x21.326.2 81.4%  
Price / Book Value ratio x4.08.8 45.7%  
Dividend payout %25.77.4 347.6%   
Avg Mkt Cap Rs m493,632621,041 79.5%   
No. of employees `00022.713.3 170.7%   
Total wages/salary Rs m31,06815,508 200.3%   
Avg. sales/employee Rs Th6,259.010,457.6 59.9%   
Avg. wages/employee Rs Th1,369.81,167.1 117.4%   
Avg. net profit/employee Rs Th569.71,491.6 38.2%   
INCOME DATA
Net Sales Rs m141,961138,961 102.2%  
Other income Rs m1,7151,663 103.1%   
Total revenues Rs m143,676140,624 102.2%   
Gross profit Rs m24,72232,056 77.1%  
Depreciation Rs m10,2663,926 261.5%   
Interest Rs m6342,568 24.7%   
Profit before tax Rs m15,53727,225 57.1%   
Minority Interest Rs m039 0.0%   
Prior Period Items Rs m3490-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,9657,444 39.8%   
Profit after tax Rs m12,92119,820 65.2%  
Gross profit margin %17.423.1 75.5%  
Effective tax rate %19.127.3 69.8%   
Net profit margin %9.114.3 63.8%  
BALANCE SHEET DATA
Current assets Rs m96,837100,015 96.8%   
Current liabilities Rs m84,19974,759 112.6%   
Net working cap to sales %8.918.2 49.0%  
Current ratio x1.21.3 86.0%  
Inventory Days Days73107 68.3%  
Debtors Days Days98110 89.1%  
Net fixed assets Rs m102,55252,350 195.9%   
Share capital Rs m829585 141.7%   
"Free" reserves Rs m121,79267,707 179.9%   
Net worth Rs m122,62170,567 173.8%   
Long term debt Rs m5,4498,472 64.3%   
Total assets Rs m218,165156,994 139.0%  
Interest coverage x25.511.6 219.8%   
Debt to equity ratio x00.1 37.0%  
Sales to assets ratio x0.70.9 73.5%   
Return on assets %6.214.3 43.6%  
Return on equity %10.528.1 37.5%  
Return on capital %12.937.7 34.2%  
Exports to sales %54.651.0 107.0%   
Imports to sales %9.418.8 49.6%   
Exports (fob) Rs m77,52070,927 109.3%   
Imports (cif) Rs m13,27426,193 50.7%   
Fx inflow Rs m81,67071,015 115.0%   
Fx outflow Rs m26,35528,799 91.5%   
Net fx Rs m55,31542,216 131.0%   
CASH FLOW
From Operations Rs m21,44417,596 121.9%  
From Investments Rs m-18,404-13,801 133.4%  
From Financial Activity Rs m-3,692-198 1,861.8%  
Net Cashflow Rs m-1,1443,597 -31.8%  

Share Holding

Indian Promoters % 25.5 54.1 47.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 8.0 67.9%  
FIIs % 35.3 27.7 127.4%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 10.2 150.0%  
Shareholders   75,885 69,601 109.0%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   TORRENT PHARMA  NATCO PHARMA  DIVIS LABORATORIES  PFIZER  ALKEM LABORATORIES  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Steady Despite North Korea Threat(RoundUp)

Global financial markets ended the week on a flat note despite North Korea once again threatening to test a hydrogen bomb in the Pacific Ocean.

Related Views on News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

India's Big and Messy Real Estate Ponzi Scheme, Just Got Messier(Vivek Kaul's Diary)

Sep 11, 2017

The question is, whether real estate buyers are financial creditors or not.

Feeling Left Out? Two Opportunities to Make Money in This Market(Daily Profit Hunter)

Sep 13, 2017

Nifty is above 10,000 once again. Have you missed the bus?

Rule-Based Investing Can Make A Lot of Money(The 5 Minute Wrapup)

Sep 16, 2017

We take a glimpse of Equitymaster's results from rule based investing.

Introducing Smart Contrarian: The Blueprint for Big Profits from Small Investments

Sep 18, 2017

Welcome to a bold, new initiative designed for the truly contrarian investor.

How To Link Aadhaar With Your Mutual Fund Investments(Outside View)

Sep 11, 2017

The Government has extended the linking of the unique Aadhaar number to nearly all financial transactions.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Sep 22, 2017 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS